Work

Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer

Year: 2024

Type: article

Abstract: Background Recently, Tintelnot et al reported that a higher concentration of the bacterially produced metabolite indole 3-acetate (3-IAA) in blood was linked to a better response to chemotherapy in people with metastatic pancreatic ductal adenocarcinoma (PDAC). Here, we aimed to extend these observations to people diagnosed with non-metastatic PDAC. Patients and methods We measured circulating 3-IAA in samples from a prospective population-based cohort of 124 individuals with borderline resectable or locally advanced PDAC who later underwent primary chemotherapy. The majority (61%) of the individuals were treated with FOLFIRINOX. We used univariable and multivariable Cox proportional hazards regression to estimate the association between pre-treatment 3-IAA and overall survival. Results The median serum 3-IAA concentration before chemotherapy was 290 (interquartile range 203–417) ng/mL. The unadjusted hazard ratio (HR) for pre-treatment log 2 (3-IAA) was 0.93, 95% confidence interval (CI) [0.74–1.16], p=0.52. When adjusting for age, ECOG, CA19-9 and tumor classification, the HR for log 2 (3-IAA) was 0.87, 95% CI [0.68–1.12], p=0.28. Conclusions Our findings suggest that the potentiating effect of 3-IAA observed in metastatic PDAC may not translate to borderline resectable or locally advanced PDAC. We recommend additional clinical validation of 3-IAA’s predictive value before implementation attempts in human studies are initiated.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2024.1488749